Strategies to reduce hemostatic activation during cardiopulmonary bypass
- PMID: 15996721
- DOI: 10.1016/j.thromres.2005.05.028
Strategies to reduce hemostatic activation during cardiopulmonary bypass
Abstract
Introduction: We evaluated whether a modified protocol for cardiopulmonary bypass (CPB) could reduced the systemic hemostatic activation associated with this procedure.
Materials and methods: The in vivo rates of thrombin, fibrin, plasmin and D-dimer generation were determined in each subject during CPB using measured levels of hemostatic factors combined with a computer model of the cardiovascular and hemostatic systems. A standard CPB group using uncoated circuits, standard heparin levels and direct shed blood reinfusion (n=9) was compared to a modified CPB group using heparin-coated circuits, shed blood collection, washing and reinfusion post-operatively, lower heparin levels and epsilon-amino-caproic acid (n=10).
Results and conclusions: Standard CPB increased average thrombin generation 9-fold, decreased fibrin generation 2-fold, increased plasmin generation 11-fold and increased fibrin degradation and D-dimer generation 19-fold. During CPB in the modified group thrombin generation was not increased beyond surgical levels, lower heparin concentrations allowed each thrombin to make more fibrin prior to inhibition, while fibrin degradation was suppressed by epsilon-amino-caproic acid. At baseline for every 100 fibrins formed only 1-2 were degraded to D-dimer. During standard CPB for every 100 fibrins generated on average 34 fibrins were degraded with some subjects showing a net fibrin loss. In contrast, in the modified CPB group for every 100 fibrins formed only 4 fibrins were degraded (p<0.0001 vs. standard group). Kinetic modeling of hemostasis in individual patients showed that a modified CPB protocol could reduce excessive thrombin generation during CPB and suppress fibrin degradation moving hemostatic regulation back towards normal.
Similar articles
-
The kinetics of plasmin inhibition by aprotinin in vivo.Thromb Res. 2005;115(4):327-40. doi: 10.1016/j.thromres.2004.09.015. Thromb Res. 2005. PMID: 15668193
-
Reducing hemostatic activation during cardiopulmonary bypass: a combined approach.Anesth Analg. 2004 May;98(5):1208-16, table of contents. doi: 10.1213/01.ane.0000108489.88613.2c. Anesth Analg. 2004. PMID: 15105189 Clinical Trial.
-
Closed cardiopulmonary bypass circuits suppress thrombin generation during coronary artery bypass grafting.Interact Cardiovasc Thorac Surg. 2010 Apr;10(4):555-60. doi: 10.1510/icvts.2009.214437. Epub 2010 Jan 8. Interact Cardiovasc Thorac Surg. 2010. PMID: 20061337 Clinical Trial.
-
Anticoagulation and anticoagulation reversal with cardiac surgery involving cardiopulmonary bypass: an update.J Cardiothorac Vasc Anesth. 1999 Aug;13(4 Suppl 1):18-29; discussion 36-7. J Cardiothorac Vasc Anesth. 1999. PMID: 10468245 Review.
-
Activation of the hemostatic system during cardiopulmonary bypass.Anesth Analg. 2011 Dec;113(6):1319-33. doi: 10.1213/ANE.0b013e3182354b7e. Epub 2011 Oct 14. Anesth Analg. 2011. PMID: 22003219 Review.
Cited by
-
Human amniotic mesenchymal stem cells alleviate lung injury induced by ischemia and reperfusion after cardiopulmonary bypass in dogs.Lab Invest. 2016 May;96(5):537-46. doi: 10.1038/labinvest.2016.37. Epub 2016 Feb 29. Lab Invest. 2016. PMID: 26927516
-
Blood management-issues: the panic of coagulopathic bleeding--is there a rational approach?J Extra Corpor Technol. 2011 Mar;43(1):P58-64. J Extra Corpor Technol. 2011. PMID: 21449242 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources